Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. has been informed by the Netherlands Authority for the Financial Markets (AFM) about a notification regarding voting rights related to the company. The notification, disclosed by Goldman Sachs Group Inc., outlines various types of shares and voting rights held indirectly by different Goldman Sachs entities. This announcement highlights the significant capital interest and voting rights distribution, which could impact QIAGEN’s shareholder structure and influence in the market.
The most recent analyst rating on (QGEN) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. They are known for their innovative solutions that enable customers to gain valuable insights from biological samples.
Average Trading Volume: 1,171,229
Technical Sentiment Signal: Buy
Current Market Cap: $9.81B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.